Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
PRO-542
Accession Number
DB05793
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

PRO 542 belongs to a new class of drugs, viral-entry inhibitor, which is intended to prevent HIV from entering and infecting cells. PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.

Pharmacodynamics
Not Available
Mechanism of action

PRO 542 binds to the viral surface glycoprotein gp120 and blocks attachment and entry of virus into CD4(+) cells.Unlike currently approved therapies that block viral replication in cells already infected with HIV, PRO 542 is an antibody-like molecule that is designed to target and neutralize the virus in the bloodstream.

Single doses of PRO 542 reduced concentrations of the human immunodeficiency (HIV) in the blood by 60% to 80% in a target population of highly treatment-experienced patients with PRO 542-sensitive virus.

TargetActionsOrganism
UFree fatty acid receptor 4Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with PRO-542.
AbituzumabThe risk or severity of adverse effects can be increased when PRO-542 is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when PRO-542 is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with PRO-542.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with PRO-542.
AducanumabThe risk or severity of adverse effects can be increased when PRO-542 is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with PRO-542.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with PRO-542.
AlirocumabThe risk or severity of adverse effects can be increased when PRO-542 is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when PRO-542 is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Castagna A, Biswas P, Beretta A, Lazzarin A: The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development. Drugs. 2005;65(7):879-904. [PubMed:15892586]
  2. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DN, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC: Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother. 2004 Feb;48(2):423-9. [PubMed:14742190]
External Links
PubChem Substance
347910233

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Taste receptor activity
Specific Function
Receptor for medium and long-chain free fatty acids (FFAs). Signals via a G(q)/G(11)-coupled pathway. Acts as a receptor for omega-3 fatty acids and mediates robust anti-inflammatory effects, parti...
Gene Name
FFAR4
Uniprot ID
Q5NUL3
Uniprot Name
Free fatty acid receptor 4
Molecular Weight
42240.72 Da

Drug created on November 18, 2007 11:27 / Updated on June 04, 2019 06:19